Background: A new pathogenic disease MESHD named COVID-19 became a global threat, first reported in Wuhan, China, in December 2019. The number of affected cases growing exponentially and now, more than 210 countries confirmed the cases TRANS. Objective: This meta-analysis aims to evaluate risk factors, the prevalence SERO of comorbidity, and clinical characteristics in COVID-19 death MESHD patients compared to survival patients that can be used as a reference for further research and clinical decisions. Methods: PubMed, Science Direct, SAGE were searched to collect data about demographic, clinical characteristics, and comorbidities of confirmed COVID-19 patients from January 1, 2020, to May 17, 2020. Meta-analysis was performed with the use of Review Manager 5.3 Results: Eighty-five studies were included in Meta-analysis, including a total number of 67,299 patients with SARS-CoV-2 infection MESHD. Males TRANS are severely affected or died than females TRANS (OR = 2.26, p < 0.00001; OR = 3.59, p < 0.00001) are severely affected, or died by COVID-19 and cases with age TRANS [≥]50 are at higher risk of death MESHD than age TRANS <50 years (OR=334.23). Presence of any comorbidity or comorbidities like hypertension MESHD hypertension HP, cardiovascular disease MESHD, diabetes, cerebrovascular disease MESHD, respiratory disease, kidney MESHD disease, liver MESHD disease MESHD, malignancy significantly increased the risk of death MESHD compared to survival (OR = 3.46, 3.16, 4.67, 2.45, 5.84, 2.68, 5.62, 2.81,2.16). Among the clinical characteristics such as fever MESHD fever HP, cough MESHD cough HP, myalgia MESHD myalgia HP, diarrhea MESHD diarrhea HP, abdominal pain MESHD abdominal pain HP, dyspnea MESHD dyspnea HP, fatigue MESHD fatigue HP, sputum production, chest tightness HP headache MESHD headache HP and nausea MESHD nausea or vomiting HP or vomiting MESHD, only fatigue MESHD fatigue HP (OR = 1.31, 95%) and dyspnea MESHD dyspnea HP increased the death MESHD significantly (OR= 1.31, 4.57). The rate of death MESHD of COVID-19 cases is 0.03-times lower than the rate of survival (OR = 0.03). Conclusion Our result indicates that male TRANS patients are affected severely or died, the rate of death MESHD is more in the age TRANS [≥]50 group, and the rate of death MESHD is affected by comorbidities and clinical symptoms.